Edesa Biotech Surges After Japan Licensing Deal for Paridiprubart

2026-11-09

Investivoq PriceTracker

Edesa Biotech, Inc. (EDSA) is up 40.0% today. Here is some analysis on what might have caused this price movement. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/11/09/3398164/0/en/edesa-biotech-announces-agreement-with-kyorin-pharmaceutical-to-develop-and-commercialize-paridiprubart-in-japan.html?print=1))

Analysis: The most likely driver is Edesa’s newly announced collaboration and license agreement with Kyorin Pharmaceutical covering paridiprubart in Japan for ARDS. Investors appear to be reacting to the upfront cash, the larger milestone opportunity, and the added external validation of one of Edesa’s lead programs. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/11/09/3398164/0/en/edesa-biotech-announces-agreement-with-kyorin-pharmaceutical-to-develop-and-commercialize-paridiprubart-in-japan.html?print=1))

Details:

Edesa announced on November 9, 2026 that it entered an exclusive Japan development and commercialization agreement with Kyorin for paridiprubart in acute respiratory distress syndrome. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/11/09/3398164/0/en/edesa-biotech-announces-agreement-with-kyorin-pharmaceutical-to-develop-and-commercialize-paridiprubart-in-japan.html?print=1))

The company said the deal includes a $12 million upfront payment, eligibility for roughly $134 million in additional milestone payments, and tiered double-digit royalties on Japan sales. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/11/09/3398164/0/en/edesa-biotech-announces-agreement-with-kyorin-pharmaceutical-to-develop-and-commercialize-paridiprubart-in-japan.html?print=1))

The SEC filing indicates Kyorin will fund development, regulatory work, and commercialization in Japan, while Edesa keeps rights outside Japan and retains manufacturing rights for the drug candidate. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1540159/000117184326007242/f8k_110926.htm?utm_source=openai))

Edesa also highlighted prior Phase 3 results showing a statistically significant reduction in 28-day mortality for paridiprubart versus placebo in hospitalized patients with respiratory failure, which likely strengthened enthusiasm around the licensing announcement. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/11/09/3398164/0/en/edesa-biotech-announces-agreement-with-kyorin-pharmaceutical-to-develop-and-commercialize-paridiprubart-in-japan.html?print=1))

Sources:

Edesa Biotech, SEC, GlobeNewswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$EDSA Hedge Fund Activity

We have seen 16 institutional investors add shares of $EDSA stock to their portfolio, and 13 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC added 561,751 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,567,035
BOXER CAPITAL MANAGEMENT, LLC added 205,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,666,650
DIADEMA PARTNERS LP removed 54,025 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $439,223
JANE STREET GROUP, LLC removed 43,256 shares (-37.4%) from their portfolio in Q2 2026, for an estimated $351,671
XTX TOPCO LTD added 35,352 shares (+inf%) to their portfolio in Q2 2026, for an estimated $287,411
COMMONWEALTH EQUITY SERVICES, LLC removed 35,003 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $284,574
HRT FINANCIAL LP added 31,531 shares (+inf%) to their portfolio in Q2 2026, for an estimated $256,347

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.